Quitting smoking is hard. A Medicare change may push doctors to give more help

Smoking-cessation counseling is widely regarded as one of the most effective, cheapest interventions in preventive medicine — yet it's far from routine in US doctor's offices. Part of the reason, according to STAT News, is financial: for years, what Medicare paid for this counseling fell well short of covering the time a doctor actually spends on it.
A newly implemented change raises the reimbursement rate for that counseling. The goal is to push doctors beyond a quick "have you thought about quitting?" and toward building an actual plan with the patient — covering nicotine replacement therapy, medication options, and follow-up visits.
Health economists stress that low reimbursement isn't just a number on a spreadsheet: in a busy practice, spending time on a poorly paid service quietly nudges doctors toward skipping it. That dynamic, they say, is part of why preventive care like smoking counseling — invisible in the moment, but valuable over years — gets systematically deprioritized.
Research shows that even a brief counseling conversation measurably raises quit rates. A doctor directly and personally advising a patient to quit can be motivating on its own — and it's a far cheaper intervention than prescribing medication.
Smoking remains the leading cause of preventable death in the US, substantially raising the risk of lung cancer, heart disease, and stroke. From a health-system perspective, persuading a patient to quit is one of the cheapest ways to avoid the long-term costs of treating them after the fact.
Experts acknowledge that a reimbursement bump alone may not be enough. Other obstacles remain — time pressure on doctors, insufficient training in cessation counseling, and the fact that patients sometimes respond defensively to the conversation.
Still, health policy experts call the reimbursement increase a step in the right direction, because financial incentives directly shape which services get prioritized inside a practice. A better-paid service fits more easily into clinical workflow.
What will really show the change's impact is data collected over the coming years: will doctors actually deliver more counseling, and will that translate into a measurable rise in patients quitting?
Some health systems, independent of the reimbursement change, are already trying to make smoking counseling a standard checklist item — a way of automating the process rather than leaving it to individual doctor discretion.
Ultimately, the change is an example of how a seemingly minor administrative adjustment can ripple out to affect the daily clinical experience of millions of patients. Quitting smoking is hard — but doctors may now have a bit more financial incentive to actually have that conversation.
Read next

Second death reported in New York City legionnaires' disease outbreak
A second person has died in a legionnaires' disease outbreak that has sickened dozens of people in New York City, health officials say, even as they report evidence the source of the bacteria has likely been eliminated.

A common antidepressant may ease long COVID's crushing fatigue, trial finds
A randomized clinical trial of nearly 400 adults found that fluvoxamine, a low-cost, decades-old antidepressant, significantly reduced fatigue and improved quality of life in people with long COVID, making it one of the first medications to show a meaningful benefit for the debilitating symptom.

Mineral sunscreen without the chalky white cast: what UCLA's new formula changes
Mineral sunscreens are prized for being gentler on skin than chemical alternatives, but they have long left users with a visible white cast. Scientists at UCLA say they have redesigned the zinc oxide particles at the heart of the problem, aiming to make mineral sunscreen usable across all skin tones.

Menopause hormone therapy: what it actually treats, and what it doesn't
Menopause hormone therapy has swung from being widely feared to widely recommended, but doctors say expectations have overtaken the evidence. Here is what the treatment reliably helps with, what it doesn't, and how the science has shifted over two decades.

FDA still points to Taylor Farms lettuce in cyclospora outbreak despite a faulty test
US regulators say they remain focused on lettuce supplied by Taylor Farms as the likely source of a multistate cyclospora outbreak, even after one laboratory test used to support that theory turned out to be faulty. Restaurant visits tied to the outbreak have started to decline.